Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synovial Fluid Biomarkers in Fasinumab Phase 3 Osteoarthritis Program
2018-001411-71Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of fasinumab in knee osteoarthritis (OA) and hip osteoarthritis (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Changes in synovial fluid biomarkers. Started Sep 2018; status: terminated.
02
Drugs
fasinumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on 2018-001411-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001411-71.